NexoBrid® is an Effective Enzymatic Agent for Eschar Removal3
Help adults and pediatric patients with deep partial thickness and/or full thickness burn wounds start towards a path to healing with effective, selective eschar removal1–3
Product illustration
NexoBrid is available as 5 g lyophilized powder (containing 4.85 g of anacaulase-bcdb) mixed in 50 g gel vehicle for treatment of up to 450 cm2 of burn area after mixing3
- For topical use only
Studies showed NexoBrid dissolves eschar and can be3:
- Applied as a 4-hour application within hours of patient presentation for earlier and more informed medical planning for healing and care1,3,4
- Remove NexoBrid after 4 hours
- Used at bedside, in the ICU, PICU, or in the OR with appropriate monitoring4,5
- Administered by burn and trauma healthcare professionals4
Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarketing use of anacaulase-bcdb. If a hypersensitivity reaction occurs, remove NexoBrid (if applicable) and initiate appropriate therapy.
Take precautions to avoid exposure to NexoBrid during preparation and handling (e.g., gloves, surgical masks, other protective coverings, as needed).
This information provided is not intended to provide medical advice or direction. Healthcare professionals should assess each situation and consider their own procedures, including treatment and pain management, for their patients as each patient’s situation will vary.
Please see Full Prescribing Information for guidance on preparation and application.
NexoBrid may provide an alternative option to surgical excision that6
- Removes eschar in adults and pediatric patients while preserving viable tissue1–3
- Dissolves eschar within a 4-hour application period3
- Remove NexoBrid after 4 hours
- May lead to more precise wound depth determination1,2
- Achieved ≥95% eschar removal in 93% of adult patients with DPT and FT thermal burns in a clinical study3
- Achieved ≥95% eschar removal 5 days sooner than SOC in a clinical study of pediatric patients3*
- Lowered the incidence of excision for eschar removal in clinical studies3
- The most common adverse reactions (>5%) in adults were pruritus, pyrexia, wound complication, anemia, vomiting and insomnia. The most common adverse reactions (>5%) in pediatric patients were pruritus, pyrexia and vomiting.
*Standard of care (SOC) included a combination of surgical and non-surgical eschar removal procedures such as: tangential, minor, avulsion, Versajet, and/or dermabrasion excision per the investigators’ discretion.
Unveiling the NexoBrid wound bed
Selective eschar removal with NexoBrid may reveal a clear view of the extent of the original injury.2,5
Before
After
Images are from a real NexoBrid patient. Individual results may vary.
About NexoBrid
NexoBrid is a mixture of proteolytic enzymes extracted from the stems of pineapple plants that dissolves burn wound eschar while preserving viable tissue.1–3
How to use NexoBrid
Find out more about the preparation, application, and removal of NexoBrid.